Autopsy report · NCT03942419

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

“Interim Analysis reviewed by Data Monitoring Committee indicated futility”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 6 months before it stopped.
• 438 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Eyenovia Inc.

Sponsor type

Industry

Conditions

Myopia

Interventions

Atropine 0.1% Ophthalmic Solution; Atropine 0.01% Ophthalmic Solution; Placebo Ophthalmic Solution

Participants

438

Sites

18

Countries

United States

Trials that died the same way

• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (79% match in meaning)
• Sevoflurane and Percutaneous Coronary Intervention by Stent
  “interim analysis suggests futility” (79% match in meaning)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
  “Based on interim analyses for futility” (79% match in meaning)
• CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)
  “Study was terminated after the planned interim analysis as the pre-defined futility threshold was met” (78% match in meaning)
• Bivalirudin Infusion for Ventricular Infarction Limitation
  “Futility at the interim analysis.” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.